ThromboGenics Microplasmin meets TG-MV-007 trial primary endpoint
ThromboGenics' second Phase III trial (TG-MV-007) assessing Microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met the primary endpoint.
ThromboGenics said that 25.3% of the 245 Microplasmin treated patients achieved resolution of their VMA at 28 days, compared to 6.2% of the 81 patients who received a placebo injection.
Microplasmin was shown to be even more effective in patients without epiretinal membrane when compared to placebo treated patients.
Reportedly, the TG-MV-007 trial also showed that Microplasmin was highly effective in treating patients who had been diagnosed with full thickness macular hole (FTMH).
The TG-MV-007 study also evaluated the visual acuity (VA) of patients which demonstrated that at the end of the study 22% of the Microplasmin treated patients had achieved at least a 10 letter (2 lines) improvement in VA without the need for vitrectomy.
Related Insight
Suppliers Directory
Axiom Real Time Metrics - EDC Solutions
As experts in EDC products and implementation, we help simplify the potential challenges of using EDC. We assist with technology, personnel and process.
Contract Research & Services > Clinical Trials > Suppliers
PolyPeptide Group - Proprietary and Generic GMP-Grade Peptides
The PolyPeptide Group is a privately-held group of manufacturing companies that focuses on proprietary and generic GMP-grade peptides for the pharmaceutical, cosmetic and biotechnological market.
Contract Research & Services > Clinical Trials > Suppliers
ikfe CRO - Diabetes and Cardiovascular Research
ikfe CRO, the experts for diabetes and cardiovascular research, provide a wide range of services to pharmaceutical and biotechnology companies across the world.
Contract Research & Services > Clinical Trials > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Clinical Trials Intelligence
Peptide Professionals
Published by PolyPeptide Group
Contract Research & Services > Clinical Trials > White Papers
Reducing Risk with the Right CRO Partner
Published by INC Research
Contract Research & Services > Clinical Trials > White Papers
Proof of Pharmacological Principle
Published by Centre for Human Drug Research
Contract Research & Services > Clinical Trials > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.